Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion.


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
11 2019
Historique:
received: 22 05 2019
accepted: 24 08 2019
pubmed: 11 9 2019
medline: 20 8 2020
entrez: 11 9 2019
Statut: epublish

Résumé

Dalbavancin is a lipoglycopeptide antibiotic with a prolonged half-life. A phase 1 study assessed dalbavancin levels in epithelial lining fluid (ELF) in 35 healthy adults using ELF bronchial microsampling up to 168 h after administration of 1,500 mg dalbavancin. The penetration of dalbavancin into ELF was 36%. ELF levels of dalbavancin exceeded the MIC

Identifiants

pubmed: 31501147
pii: AAC.01024-19
doi: 10.1128/AAC.01024-19
pmc: PMC6811436
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Teicoplanin 61036-62-2
dalbavancin 808UI9MS5K

Types de publication

Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2019 Rappo et al.

Références

N Engl J Med. 2014 Jun 5;370(23):2169-79
pubmed: 24897082
J Antimicrob Chemother. 1999 Aug;44(2):179-92
pubmed: 10473224
Antimicrob Agents Chemother. 2015 Dec;59(12):7833-6
pubmed: 26392492
Antimicrob Agents Chemother. 2007 May;51(5):1633-42
pubmed: 17307987
Respir Med. 2009 Jan;103(1):35-40
pubmed: 18930648
J Pharmacol Pharmacother. 2017 Apr-Jun;8(2):77-79
pubmed: 28706403
Chest. 2001 Apr;119(4):1114-22
pubmed: 11296178
J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Sep 1;879(25):2632-41
pubmed: 21831727
Am J Respir Crit Care Med. 2003 Dec 1;168(11):1304-7
pubmed: 12904323
Respirology. 2008 Mar;13(2):221-6
pubmed: 18339019
Clin Infect Dis. 2016 Mar 1;62(5):545-51
pubmed: 26611777
Infect Dis Ther. 2015 Sep;4(3):245-58
pubmed: 26341488
Int J Antimicrob Agents. 2015 Apr;45(4):393-8
pubmed: 25681068

Auteurs

Urania Rappo (U)

Allergan plc, Madison, New Jersey, USA rappou01@gmail.com.

Michael W Dunne (MW)

Allergan plc, Madison, New Jersey, USA.

Sailaja Puttagunta (S)

Allergan plc, Madison, New Jersey, USA.

James S Baldassarre (JS)

Allergan plc, Madison, New Jersey, USA.

Shengfang Su (S)

Allergan plc, Madison, New Jersey, USA.

Daksha Desai-Krieger (D)

Allergan plc, Madison, New Jersey, USA.

Megumi Inoue (M)

SOUSEIKAI Hakata Clinic, Fukuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH